SCHEMBL761635

SCHEMBL761635

CC1=NN(C)Cc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
PKM P14618 3/20 0.40
KDM4E B2RXH2 3/20 0.40
TP53 P04637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.39
LMNA P02545 4/20 0.39
POLB P06746 3/20 0.39
MAPT P10636 5/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
IDO1 P14902 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
THRB P10828 1/20 0.38
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761240 0.81 SETD7 (0.44) MAOAMAOBADRA1ACHRM2HTR1A
SCHEMBL17559143 0.78 HSD11B1 (0.40) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL10745421 0.76 IDO1 (0.42) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL10746119 0.73 KDM4E (0.42) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL761827 0.72 ALDH1A1 (0.41) SMN1; SMN2KDM4ETSHRKMT2AMAPT
Hydrochloric Acid SCHEMBL10744723 0.72 KDM4E (0.41) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL1649346 0.69 MAOA (0.56) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL8170948 0.66 TSHR (0.54) SMN1; SMN2KDM4ETSHRALDH1A1HPGD
SCHEMBL1490708 0.64 MAOA (0.40) NPC1RAB9ASMN1; SMN2KMT2ALMNA
SCHEMBL24180108 0.63 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138182-B2 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-03-20 US disclosed
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2010-04-08 US disclosed
US-7655804-B2 N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT SERPINB1, CTSZ, ELANE NPC1 226/4885RAB9A 2964/4885SMN1; SMN2 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.